KMR Group Leads New Enrollment Metrix Forum
KMR GROUP, a firm specializing on biopharmaceutical R&D performance, has formed the Enrollment Metrix Forum. As companies strive to implement best recruitment practices, the Forum offers an opportunity to explore critical recruitment issues as well as analyze recruitment processes. Amgen, AZ, Bayer, BMS, J&J, Lilly, Merck, Pfizer, Roche, Shire and UCB are among the inaugural members.
The Enrollment Metrix Forum serves an industry leadership role for the exchange of ideas and the exploration of issues related to enrollment, offering insights that will prove of value to participants; including the use and identification of enrollment performance metrics, how best to incorporate metrics into the planning process, and using KPIs to identify key performance opportunities. The discussions are flexible, and representatives are encouraged to shape their direction.
Results of these exchanges are provided to members in a report format as part of our Enrollment Special Topics Series. The reports, which take input via members through discussion and surveys, are designed to add insight into the rapidly changing recruitment landscape. In addition, members will have access to the KMR Enrollment Metrix Forum website which offers access to the reports in addition to membership information, press releases and an on-line glossary of terms.
The first meeting took focused on "Defining the Critical Metrics for Evaluating Recruitment Processes". Participants will meet again in December. The first report will be an analysis of key recruitment processes and their associated metrics.
Companies interested in learning more about the Enrollment Metrix Forum are encouraged to contact KMR.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
